The US Food and Drug Administration has asked manufacturers of gonadotropin-releasing hormone agonists, which are used to treat men with prostate cancer, to carry warnings on their labels about the potential risk of heart disease and diabetes. ---Subscribe to MedNous to access this article--- Regulation & Policy
